Explore
Validate
LearnMAB124-100
antibody from R&D Systems
Targeting: TNFSF13B
BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB124-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human BAFF/BLyS/TNFSF13B Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human BAFF in direct ELISAs.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
Q9Y275- Isotype
- IgG
- Antibody clone number
- 148725
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis.
Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis.
IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
IL-15 expression on RA synovial fibroblasts promotes B cell survival.
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
Touil H, Kobert A, Lebeurrier N, Rieger A, Saikali P, Lambert C, Fawaz L, Moore CS, Prat A, Gommerman J, Antel JP, Itoyama Y, Nakashima I, Bar-Or A, Canadian B Cell Team in MS.
Journal of neuroinflammation 2018 Apr 19;15(1):114
Journal of neuroinflammation 2018 Apr 19;15(1):114
Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis.
Chang LY, Li Y, Kaplan DE
Scientific reports 2016 Nov 18;6:36862
Scientific reports 2016 Nov 18;6:36862
IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
Giacomini E, Severa M, Rizzo F, Mechelli R, Annibali V, Ristori G, Riccieri V, Salvetti M, Coccia EM
European journal of immunology 2013 Jul;43(7):1963-72
European journal of immunology 2013 Jul;43(7):1963-72
IL-15 expression on RA synovial fibroblasts promotes B cell survival.
Benito-Miguel M, García-Carmona Y, Balsa A, Bautista-Caro MB, Arroyo-Villa I, Cobo-Ibáñez T, Bonilla-Hernán MG, Pérez de Ayala C, Sánchez-Mateos P, Martín-Mola E, Miranda-Carús ME
PloS one 2012;7(7):e40620
PloS one 2012;7(7):e40620
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ
Blood 2006 Jun 1;107(11):4540-8
Blood 2006 Jun 1;107(11):4540-8
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by BAFF/BLyS/TNFSF13B and Neutralization by Human BAFF/BLyS/TNFSF13B Antibody. Recombinant Human BAFF/BLyS/TNFSF13B (Catalog # 2149-BF) stimulates proliferation in mouse B cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human BAFF/BLyS/TNFSF13B (5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human BAFF/BLyS/TNFSF13B Monoclonal Antibody (Catalog # MAB124). At 20 µg/mL, this anti-BAFF/BLyS/TNFSF13B antibody will neutralize >60% of Recombinant Human BAFF/BLyS/TNFSF13B-induced proliferation of mouse B cells.
